Fibroblast activation protein inhibitor (FAPI) is a promising tracer in oncologic positron
emission tomography/computed tomography (PET/CT). Numerous studies have …

Pancreatic cancer remains among the malignancies with the worst outcomes. Survival has
been improving, but at a slower rate than other cancers. Multimodal treatment, including …

This expedited systematic review aims to provide the first overview of the different Fibroblast
activation protein inhibitor (FAPI) PET scan procedures in the literature and discuss how to …

Background: Previously considered inoperable patients (borderline resectable, locally
advanced, synchronous oligometastatic or metachronous pancreatic adenocarcinoma …

Metastatic malignancies have limited management strategies and variable treatment
responses. Cancer cells develop beside and depend on the complex tumor …

Klatskin tumor, also known as hilar cholangiocarcinoma, was clearly demonstrated in this
case report by contrasting 68 Ga-FAPI and 18 F-FDG PET/CT in the same patient. This …

Background: FAP radiopharmaceuticals show promise for cancer diagnosis; however, their
limited tumor residency hinders treatment. This study compared two FAPi derivatives, DOTA …

Hepatocellular carcinoma and intrahepatic cholangiocarcinoma are the two most common
primary malignant tumors of the liver. The similarities and variations in imaging …

Multimodal information is increasingly necessary for clinical care, providing data related to
anatomy, physiology, or metabolism through a combination of diagnostic tests such as …

Background Recent studies have shown the potential of fibroblast activating protein inhibitor
(FAPI) PET imaging for pancreatic cancer assessment. Purpose This article is dedicated to …